$PGEN News

Precigen Inc (NASDAQ:PGEN) Flashes Perfect Technical Rating and Explosive Sales Growth in Minervini Screen

Precigen: Entering The Oncology 'Sweet Spot'

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $14

Precigen Says FDA Grants Orphan Drug Exclusivity For PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis

Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

Precigen (PGEN): The Best Penny Stock to Buy for Long Term

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Precigen, Inc. Q1 2026 Earnings Call Summary

Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11

HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11

Precigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

Precigen Q1 Earnings Call Highlights

Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript

Precigen (PGEN) Q1 2026 Earnings Transcript

Transcript: Precigen Q1 2026 Earnings Conference Call

Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates